HOOKIPA Pharma Provides Update on Business Priorities and
HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious...
Source: globenewswire.com
Page 2 - Nasdaq Hook News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nasdaq Hook. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nasdaq Hook Today - Breaking & Trending Today
Hookipa Pharma (NASDAQ:HOOK) Trading Down 16.5%
Shares of Hookipa Pharma Inc (NASDAQ:HOOK – Get Free Report) were down 16.5% during mid-day trading on Monday . The stock traded as low as $0.71 and last traded at $0.72. Approximately 9,262,100 shares were traded during trading, an increase of 749% from the average daily volume of 1,090,797 shares. The stock had previously closed […]
Source: etfdailynews.com
Hookipa Pharma Inc (HOOK) Shares Rise Despite Market Challenges
The stock of Hookipa Pharma Inc (NASDAQ: HOOK) has increased by 10.21 when compared to last closing price of 0.45. Despite this, the company has experienced a 18.69% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-02 that NEW YORK and VIENNA, Austria, Nov.
Source: newsheater.com
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line...
Source: globenewswire.com
Hookipa Pharma's (HOOK) Outperform Rating Reaffirmed at Royal Bank of Canada
Royal Bank of Canada reiterated their outperform rating on shares of Hookipa Pharma (NASDAQ:HOOK – Free Report) in a research report released on Wednesday morning, Benzinga reports. Royal Bank of Canada currently has a $7.00 target price on the stock. Several other equities research analysts have also issued reports on HOOK. HC Wainwright lowered their […]
Source: wkrb13.com